BLISS index for analyzing knee osteoarthritis trials data

被引:17
作者
Bellamy, Nicholas [1 ]
Bell, Mary J.
Pericak, Dan
Goldsmith, Charlie H.
Torrance, George W.
Raynauld, Jean-Pierre
Walker, Valery
Tugwell, Peter
Polisson, Richard
机构
[1] Univ Queensland, CONROD, Brisbane, Qld 4006, Australia
[2] Univ Toronto, Sunnybrook Womens Coll Hlth Sci Ctr, Dept Rheumatol & Clin Epidemiol, Toronto, ON M4N 3M5, Canada
[3] i3 Innovus, Dept Hlth Econ & Outcomes Res, Burlington, ON L7L 6B8, Canada
[4] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada
[5] Univ Montreal, Montreal Inst Rheumatol, Dept Med, Montreal, PQ H2L 1S6, Canada
[6] Univ Ottawa, Dept Med, Ctr Global Hlth, Inst Populat Hlth, Ottawa, ON K1N 6N5, Canada
[7] Genzyme Corp, Clin Res, Cambridge, MA 02139 USA
关键词
effectiveness; Hylan G-F 20; osteoarthritis; randomized controlled trial; state attainment; WOMAC index;
D O I
10.1016/j.jclinepi.2006.04.004
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives: Different pain thresholds were investigated, using the WOMAC Pain Scale (WOMAC-P) to determine if they could differentiate between treatment groups (hylan G-F 20 vs. appropriate care) at low and very low levels of state attainment in patients with knee osteoarthritis (OA). A method, termed the BLISS (Bellamy et a]. Low Intensity Symptom State-attainment) Index, for analyzing OA knee clinical trials data, was proposed. Study Design and Setting: Five analyses were performed: time to first BLISS day, BLISS days over 12 months, patients with a BLISS response at month 12, patients with a BLISS response at any time, and number of BLISS periods over 12 months. For each analysis, five levels of WOMAC-P were examined: <= 5 normalized units (NU), <= 10, <= 15, <= 20, and <= 25 (higher = more pain). Results: More patients in the hylan G-F 20 group achieved BLISS states in all five analyses. These differences were statistically significant for all pain threshold levels except <= 5 NU. Conclusion: Five methods of measuring BLISS attainment using four prespecified threshold levels of pain were able to statistically discriminate between treatment groups. This method may potentially provide an approach, to defining which patients not only improve but also achieve a good state of health, at low and very low levels of pain intensity. BLISS-10 is a therapeutically attainable very low symptom state at which clinically important, statistically significant between-group differences are detectable, and therefore may provide a benchmark against which therapeutic interventions can be assessed. However, the value to patients, of this and other low and very low intensity pain states, requires further elaboration. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:124 / 132
页数:9
相关论文
共 24 条
[1]
Design and conduct of clinical trials in patients with osteoarthritis: Recommendations from a task force of the Osteoarthritis Research Society - Results from a workshop [J].
Altman, R ;
Brandt, K ;
Hochberg, M ;
MOskowitz, R ;
Bellamy, N ;
Bloch, DA ;
Buckwalter, J ;
Dougados, M ;
Ehrlich, G ;
Lequesne, M ;
Lohmander, S ;
Murphy, WA ;
RosarioJansen, T ;
Schwartz, B ;
Trippel, S .
OSTEOARTHRITIS AND CARTILAGE, 1996, 4 (04) :217-243
[2]
Altman RD, 2000, ARTHRITIS RHEUM-US, V43, P1905
[3]
Bellamy N, 2004, OSTEOARTHR CARTILAGE, V12, pS69
[4]
Bellamy N, 2002, ARTHRITIS RHEUM-US, V46, pS159
[5]
Bellamy N, 1997, J RHEUMATOL, V24, P799
[6]
Bellamy N, 2001, J RHEUMATOL, V28, P427
[7]
BELLAMY N, 1988, J RHEUMATOL, V15, P1833
[8]
BELLAMY N, 1994, OSTEOARTHRITIS CA S1, V2, P37
[9]
Bellamy N, 1993, MUSCULOSKELETAL CLIN
[10]
Boers M, 2003, J RHEUMATOL, V30, P1112